Low-dose decitabine-intensified modified conditioning regimen alleviates aGVHD in AML/MDS patients treated with allogeneic hematopoietic stem cell transplantation

Low-dose decitabine-intensified modified conditioning regimen alleviates aGVHD in AML/MDS patients treated with allogeneic hematopoietic stem cell transplantation

BackgroundThe widespread adoption of Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) has significantly improved the survival rates of patients with hematological malignancies. However, Graft-Versus-Host Disease (GVHD) remains a formidable complication, threatening patient prognosis. R...

Full description

Bibliographic Details
Main Authors:	Jinye Zhu, Qingya Wang, Hanyun Ren, Yujun Dong, Yue Yin, Qian Wang, Zeyin Liang, Wei Liu, Qingyun Wang, Bingjie Wang, Yuan Li
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-10-01
Series:	Frontiers in Immunology
Subjects:	low-dose decitabine conditioning regimen AML/MDS allogeneic hematopoietic stem cell transplantation graft versus host disease
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1274492/full

Similar Items

Reciprocal regulation of TWIST1 and OGT determines the decitabine efficacy in MDS/AML
by: Hongjiao Li, et al.
Published: (2023-09-01)

Pharmacokinetic and pharmacodynamic analysis of 5-aza-2’-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy
by: Karahoca Metin, et al.
Published: (2013-02-01)

Biglycan as a mediator of proinflammatory response and target for MDS and sAML therapy
by: Christoforos K. Vaxevanis, et al.
Published: (2023-12-01)

Patients with AML-MRC benefit from decitabine in combination with low-dose G-CSF, cytarabine and aclarubicin: A single center cohort study
by: Jing Liu, et al.
Published: (2022-01-01)

PT-Cy combined with ruxolitinib and tocilizumab prevents aGVHD after haploidentical HSCT
by: BAI Haocheng, et al.
Published: (2020-09-01)

p53 biology and reactivation for improved therapy in MDS and AML
by: Joanna E. Zawacka
Published: (2024-03-01)

Clonal MDS/AML cells with enhanced TWIST1 expression reprogram the differentiation of bone marrow MSCs
by: Hongjiao Li, et al.
Published: (2023-11-01)

Identification of a Complex Karyotype Signature with Clinical Implications in AML and MDS-EB Using Gene Expression Profiling
by: Cheonghwa Lee, et al.
Published: (2023-11-01)

Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS
by: Jeroen Janssen, et al.
Published: (2021-02-01)

Decitabine shows anti-acute myeloid leukemia potential via regulating the miR-212-5p/CCNT2 axis
by: Xing Lina, et al.
Published: (2020-12-01)

Prediction of Response and Survival Following Treatment with Azacitidine for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation
by: Christina Rautenberg, et al.
Published: (2020-08-01)

The effect of decitabine-combined minimally myelosuppressive regimen bridged allo-HSCT on the outcomes of pediatric MDS from 10 years’ experience of a single center
by: Junyan Gao, et al.
Published: (2022-05-01)

RNA INTERFERENCE (RNAI): AN EFFECTIVE WAY TO DEVELOP RATIONAL COMBINATION THERAPIES WITH HYPOMETHYLATING AGENTS IN ACUTE LEUKAEMIAS AND MYELODYSPLASTIC SYNDROME
by: Raoul Tibes
Published: (2013-08-01)

Lymphocyte Exhaustion in AML Patients and Impacts of HMA/Venetoclax or Intensive Chemotherapy on Their Biology
by: Dmitry Zhigarev, et al.
Published: (2022-07-01)

A favorable inductive remission rate for decitabine combined with chemotherapy as a first course in <60‐year‐old acute myeloid leukemia patients with myelodysplasia syndrome features
by: Fengqi Liu, et al.
Published: (2019-09-01)

Decitabine-Containing Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Intermediate- and High-Risk Myelodysplastic Syndrome/Acute Myeloid Leukemia: Potential Decrease in the Incidence of Acute Graft versus Host Disease
by: Wang QY, et al.
Published: (2019-12-01)

Effects of decitabine on allogeneic immune reactions of donor lymphocyte infusion via activation of dendritic cells
by: Yong-Rim Kwon, et al.
Published: (2020-09-01)

Long‐term remission of extramedullary cutaneous relapse of acute myeloid leukaemia (leukaemia cutis) treated with decitabine‐venetoclax
by: Denise Maravalle, et al.
Published: (2022-05-01)

Innovations in conditioning and post-transplant maintenance in AML: genomically informed revelations on the graft-versus-leukemia effect
by: H. Moses Murdock, et al.
Published: (2024-03-01)

Maintenance Treatment With Low-Dose Decitabine After Allogeneic Hematopoietic Cell Transplantation in Patients With Adult Acute Lymphoblastic Leukemia
by: Jia Liu, et al.
Published: (2021-08-01)

Allogenic hematopoietic stem cell transplantation outcomes of patients aged ≥ 55 years with acute myeloid leukemia or myelodysplastic syndromes in China: a retrospective study
by: Lu Gao, et al.
Published: (2024-01-01)

Donor γδT Cells Promote GVL Effect and Mitigate aGVHD in Allogeneic Hematopoietic Stem Cell Transplantation
by: Yuan Song, et al.
Published: (2020-10-01)

A phase II trial of decitabine, bortezomib and pegylated liposomal doxorubicin for the treatment of relapsed or refractory AML
by: Brian A. Jonas, et al.
Published: (2023-01-01)

Bladder Myeloid Sarcoma with TP53 mutated Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap syndrome: Response to Decitabine-Venetoclax regimen
by: Nikeeta Mandhan, et al.
Published: (2022-01-01)

Allogeneic haematopoietic stem cell transplantation with decitabine-containing preconditioning regimen in TP53-mutant myelodysplastic syndromes: A case study
by: Yuxin Wang, et al.
Published: (2022-07-01)

Smart Conditioning with Venetoclax-Enhanced Sequential FLAMSA + RIC in Patients with High-Risk Myeloid Malignancies
by: Felicitas Schulz, et al.
Published: (2024-01-01)

Immune checkpoint gene VSIR predicts patient prognosis in acute myeloid leukemia and myelodysplastic syndromes
by: Kevin Yao, et al.
Published: (2023-03-01)

HLA Evolutionary Divergence as a Prognostic Marker for AML Patients Undergoing Allogeneic Stem Cell Transplantation
by: Malte Roerden, et al.
Published: (2020-07-01)

Pre-Clinical Evaluation of the Hypomethylating Agent Decitabine for the Treatment of T-Cell Lymphoblastic Lymphoma
by: Lien Provez, et al.
Published: (2023-01-01)

Haematologic malignancies with unfavourable gene mutations benefit from donor lymphocyte infusion with/without decitabine for prophylaxis of relapse after allogeneic HSCT: A pilot study
by: Rui Zhang, et al.
Published: (2021-05-01)

A Novel Cognition of Decitabine: Insights into Immunomodulation and Antiviral Effects
by: Ji Xiao, et al.
Published: (2022-03-01)

Human Amniotic Mesenchymal Stem Cells Inhibit aGVHD by Regulating Balance of Treg and T Effector Cells
by: Gao Y, et al.
Published: (2021-08-01)

Gene Expression Profiles Identify Biomarkers of Resistance to Decitabine in Myelodysplastic Syndromes
by: Seungyoun Kim, et al.
Published: (2021-12-01)

Risk Stratification, Measurable Residual Disease, and Outcomes of AML Patients with a Trisomy 8 Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
by: Donata Backhaus, et al.
Published: (2021-11-01)

Hairpin-bisulfite sequencing of cells exposed to decitabine documents the process of DNA demethylation
by: Issam M Mayyas, et al.
Published: (2021-11-01)

Gemtuzumab ozogamicin (GO) as monotherapy and in combination with hypomethylation agents in the treatment of acute myeloid leukemia: a systematic meta-analysis
by: Jun Li, et al.
Published: (2022-12-01)

The Elephant in The Room: AML Relapse Post Allogeneic Hematopoietic Cell Transplantation
by: Iman Abou Dalle, et al.
Published: (2022-01-01)

Clinical and Cytogenetic Characterization of Early and Late Relapses in Patients Allografted for Myeloid Neoplasms with a Myelodysplastic Component
by: Victoria Platte, et al.
Published: (2022-12-01)

Clinical, hematological, and cytogenetic profile of adult myelodysplastic syndrome in a tertiary care center
by: Narayanan S
Published: (2017-02-01)

A Retrospective Observation of Treatment Outcomes Using Decitabine-Combined Standard Conditioning Regimens Before Transplantation in Patients With Relapsed or Refractory Acute Myeloid Leukemia
by: Yuhang Li, et al.
Published: (2021-08-01)